Summary
Zeria Pharmaceutical Co., Ltd. (Zeria), formerly Zeria Yakusho Kenkyusho Co., Ltd. is a pharmaceutical company that manufacture, sells, imports and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, industrial chemicals and reagents and other products. The company provides ethical and OTC drugs and products. Its ethical products include gastrointestinal field and other products. Zeria offers OTC drugs and products such as self-prevention, remedies for gastrointestinal diseases, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, and hemorroidal remedies, among others. The company also offers products of cosmetics, health foods, alcoholic beverages, carbonated beverages, food additives, livestock feed, hygienic goods, medical devices, and others. Zeria is headquartered in Chuo-ku, Japan.
Zeria Pharmaceutical Co., Ltd. (4559) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Zeria Pharmaceutical Co., Ltd., Medical Devices Deals, 2010 to YTD 2016 9
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Tillotts Pharma Acquires Entocort from AstraZeneca 12
Venture Financing 13
Cancer Prevention Pharma Raises US$0.4 Million In Venture Financing 13
Cancer Prevention Pharma Raises Funds Through Venture Financing 14
Cancer Prevention Pharma Secures US$0.55 Million In Venture Financing 16
Partnerships 17
Solid Form Solutions Enters Into Co-Promotion Agreement With Tillotts Pharma 17
Cambrex Enters Into Co-Development Agreement With Tillotts Pharma 18
Cancer Prevention Pharma Partners with SWOG 19
Licensing Agreements 20
Sucampo Pharma Enters into Option Agreement with Cancer Prevention Pharma 20
Tillotts Pharma Enters into Licensing Agreement with Numab 21
Eisai Enters into Licensing Agreement with Zeria Pharma for Proton Pump Inhibitor 22
Tillotts Pharma Amends Licensing Agreement with Cancer Prevention Pharma 23
Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 25
Tillotts Pharma Enters Into Licensing Agreement With The School of Pharmacy 27
Equity Offering 28
Cancer Prevention Pharma to Raise up to USD27 Million in IPO 28
Debt Offering 30
Cancer Prevention Pharma Raises USD2.3 Million in Private Placement of Notes Due 2018 30
Acquisition 31
Zeria Pharma Acquires Remaining 15% Stake In ZPD From Rorvig 31
Zeria Pharma Acquires Biofac 32
Zeria Pharmaceutical Co., Ltd. - Key Competitors 33
Key Employees 34
Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38
List of Tables
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Key Facts, 2015 1
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Zeria Pharmaceutical Co., Ltd., Deals By Therapy Area, 2010 to YTD 2016 8
Zeria Pharmaceutical Co., Ltd., Medical Devices Deals, 2010 to YTD 2016 9
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Tillotts Pharma Acquires Entocort from AstraZeneca 12
Cancer Prevention Pharma Raises US$0.4 Million In Venture Financing 13
Cancer Prevention Pharma Raises Funds Through Venture Financing 14
Cancer Prevention Pharma Secures US$0.55 Million In Venture Financing 16
Solid Form Solutions Enters Into Co-Promotion Agreement With Tillotts Pharma 17
Cambrex Enters Into Co-Development Agreement With Tillotts Pharma 18
Cancer Prevention Pharma Partners with SWOG 19
Sucampo Pharma Enters into Option Agreement with Cancer Prevention Pharma 20
Tillotts Pharma Enters into Licensing Agreement with Numab 21
Eisai Enters into Licensing Agreement with Zeria Pharma for Proton Pump Inhibitor 22
Tillotts Pharma Amends Licensing Agreement with Cancer Prevention Pharma 23
Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 25
Tillotts Pharma Enters Into Licensing Agreement With The School of Pharmacy 27
Cancer Prevention Pharma to Raise up to USD27 Million in IPO 28
Cancer Prevention Pharma Raises USD2.3 Million in Private Placement of Notes Due 2018 30
Zeria Pharma Acquires Remaining 15% Stake In ZPD From Rorvig 31
Zeria Pharma Acquires Biofac 32
Zeria Pharmaceutical Co., Ltd., Key Competitors 33
Zeria Pharmaceutical Co., Ltd., Key Employees 34
Zeria Pharmaceutical Co., Ltd., Other Locations 35
Zeria Pharmaceutical Co., Ltd., Subsidiaries 36
List of Figures
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Zeria Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Zeria Pharmaceutical Co., Ltd., Medical Devices Deals, 2010 to YTD 2016 9
